Dynamics in the costs of criminality among opioid dependent individuals

Drug and Alcohol Dependence

Volumn 144, Issue , 2014, Pages 193-200

  Krebs, Emanuel ^a   Kerr, Thomas ^a,b   Montaner, Julio ^a,b   Wood, Evan ^a,b   Nosyk, Bohdan ^a,c  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Costs of criminality; Methadone maintenance treatment; Opioid use; Relapse; Stimulant use; Treatment outcomes

Indexed keywords

METHADONE; PLACEBO; NARCOTIC ANALGESIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CANADA; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COSTS OF CRIMINALITY; CRIMINAL BEHAVIOR; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FEMALE; GENDER; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; SELF REPORT; SOCIOECONOMICS; STATISTICAL ANALYSIS; STATISTICAL MODEL; AGED; COHORT ANALYSIS; COST OF ILLNESS; CRIME; ECONOMICS; FOLLOW UP; MIDDLE AGED; OFFENDER; OPIOID-RELATED DISORDERS; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANALGESICS, OPIOID; COHORT STUDIES; COST OF ILLNESS; CRIME; CRIMINALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84908890393     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.09.007     Document Type: Article

References (48)

1. Anglin M.D., Nosyk B., Jaffe A., Urada D., Evans E. Offender diversion into substance use disorder treatment: the economic impact of California's proposition 36. Am. J. Public Health 2013, 103:1096-1102.
2. Bayer P., Hjalmarsson R., Pozen D. Building criminal capital behind bars: peer effects in juvenile corrections. Q. J. Econ. 2009, 124:105-147.
3. Bell J., Burrell T., Indig D., Gilmour S. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. Drug Alcohol Depend. 2006, 81:55-61.
4. Best D., Sidwell C., Gossop M., Harris J., Strang J. Crime and expenditure amongst polydrug misusers seeking treatment the connection between prescribed methadone and crack use, and criminal involvement. Br. J. Criminol. 2001, 41:119-126.
5. Bovasso G., Cacciola J. The long-term outcomes of drug use by methadone maintenance patients. J. Behav. Health Serv. Res. 2003, 30:290-303.
6. Bukten A., Roislien J., Skurtveit S., Waal H., Gossop M., Clausen T. A day-by-day investigation of changes in criminal convictions before and after entering and leaving opioid maintenance treatment: a national cohort study. BMC Psychiatry 2013, 13:1-7.
7. Castells X., Kosten T.R., Capella D., Vidal X., Colom J., Casas M. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: a systematic review and meta-analysis of controlled clinical trials. Am. J. Drug Alcohol Abuse 2009, 35:339-349.
8. Chisholm D., Doran C., Shibuya K., Rehm J. Comparative cost-effectiveness of policy instruments for reducing the global burden of alcohol, tobacco and illicit drug use. Drug Alcohol Rev. 2006, 25:553-565.
9. College of Physicians and Surgeons of British Columbia Methadone Maintenance Program: Clinical Practice Guideline 2014, College of Physicians and Surgeons of British Columbia, https://www.cpsbc.ca/files/pdf/MMP-Clinical-Practice-Guideline-2014-02.pdf (accessed on 30 March 2014).
10. Collins J.J., Hubbard R.L., Rachal J. Expensive drug use and illegal income: a test of explanatory hypotheses. Criminology 1985, 23:743-764.
11. DeBeck K., Shannon K., Wood E., Li K., Montaner J., Kerr T. Income generating activities of people who inject drugs. Drug Alcohol Depend. 2007, 91:50-56.
12. Dijkgraaf M.G.W., van der Zanden B.P., de Borgie C.A.J.M., Blanken P., van Ree J.M., van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ 2005, 330:1297.
13. Dobler-Mikola A., Hättenschwiler J., Meili D., Beck T., Böni E., Modestin J. Patterns of heroin, cocaine and alcohol abuse during long-term methadone maintenance treatment. J. Subst. Abuse Treat. 2005, 29:259-265.
14. Doran C.M. Economic evaluation of interventions to treat opiate dependence: a review of the evidence. PharmacoEconomics 2008, 26:371-393.
15. French M.T., McGeary K.A., Chitwood D.D., McCoy C.B., Inciardi J.A., McBride D. Chronic drug use and crime. Subst. Abuse 2000, 21:95-109.
16. Galai N., Safaeian M., Vlahov D., Bolotin A., Celentano D.D. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort, 1988-2000: description and determinants. Am. J. Epidemiol. 2003, 158:695-704.
17. Garrison L.P., Mansley E.C., Abbott T.A., Bresnahan B.W., Hay J.W., Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force Report-Part II. Value Health 2010, 13:8-13.
18. Glaeser E.L., Sacerdote B., Scheinkman J.A. Crime and social interactions. Q. J. Econ. 1996, 111:507-548.
19. Hser Y.I., Longshore D., Anglin M.D. The life course perspective on drug use: a conceptual framework for understanding drug use trajectories. Eval. Rev. 2007, 31:515-547.
20. Johnson B.D., Golub A. The potential for accurately measuring behavioral and economic dimensions of consumption, prices, and markets for illegal drugs. Drug Alcohol Depend. 2007, 90(Suppl. 1):16-26.
21. Johnson B.D., Taylor A., Golub A. Research note: how accurate are arrestees' self-reports of their criminal justice histories?. Justice Res. Policy 2005, 7:81-102.
22. Marsch L.A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998, 93:515-532.
23. McCollister K.E., French M.T., Fang H. The cost of crime to society: new crime-specific estimates for policy and program evaluation. Drug Alcohol Depend. 2010, 108:98-109.
24. Miller N.S., Gold M.S. Criminal activity and crack addiction. Subst. Use Misuse 1994, 29:1069-1078.
25. National Drug Intelligence Center The Economic Impact of Illicit Drug Use on American Society 2011, U.S. Department Of Justice, http://www.justice.gov/archive/ndic/pubs44/44731/44731p.pdf (accessed on 17 January 2014), (Product No. 2011-Q0317-002).
26. Nosyk B., MacNab Y.C., Sun H., Marsh D.C., Fischer B., Schechter M.T., Anis A.H. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am. J. Epidemiol. 2009, 170:783-792.
27. Nosyk B., Guh D.P., Bansback N.J., Oviedo-Joekes E., Brissette S., Marsh D.C., Meikleham E., Schechter M.T., Anis A.H. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ 2012, 184:317-328.
28. Nosyk B., Anglin M.D., Brecht M.L., Lima V.D., Hser Y.I. Characterizing durations of heroin abstinence in the California civil addict program: results from a 33-year observational cohort study. Am. J. Epidemiol. 2013, 177:675-682.
29. Nurco D.N. A long-term program of research on drug use and crime. Subst. Use Misuse 1998, 33:1817-1837.
30. Oliver P., Keen J., Rowse G., Ewins E., Griffiths L., Mathers N. The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service. Addiction 2010, 105:732-739.
31. Office of the National Drug Control Policy National Drug Control Strategy: FY 2013 Budget and Performance Summary 2013, Office of the National Drug Control Policy, http://www.whitehouse.gov/sites/default/files/ondcp/fy2013_drug_control_budget_and_performance:summary.pdf (accessed on 15 January 2014).
32. Prendergast M.L., Podus D., Chang E., Urada D. The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. Drug Alcohol Depend. 2002, 67:53-72.
33. Rajkumar A.S., French M.T. Drug abuse, crime costs, and the economic benefits of treatment. J. Quant. Criminol. 1997, 13:291-323.
34. Rehm J., Gnam W., Popova S., Baliunas D., Brochu S., Fischer B., Patra J., Sarnocinska-Hart A., Taylor B. The costs of alcohol, illegal drugs, and tobacco in Canada, 2002. J. Stud. Alcohol Drugs 2007, 68:886.
35. Schwartz R.P., Highfield D.A., Jaffe J.H., Brady J.V., Butler C.B., Rouse C.O., Callaman J.M., O'Grady K.E., Battjes R.J. A randomized controlled trial of interim methadone maintenance. Arch. Gen. Psychiatry 2006, 63:102-109.
36. Schwartz R.P., Jaffe J.H., Highfield D.A., Callaman J.M., O'Grady K.E. A randomized controlled trial of interim methadone maintenance: 10-month follow-up. Drug Alcohol Depend. 2007, 86:30-36.
37. Schwartz R.P., Alexandre P.K., Kelly S.M., O'Grady K.E., Gryczynski J., Jaffe J.H. Interim versus standard methadone treatment: a benefit-cost analysis. J. Subst. Abuse Treat. 2014, 46:306-314.
38. Stewart D., Gossop M., Marsden J., Rolfe A. Drug misuse and acquisitive crime among clients recruited to the National Treatment Outcome Research Study (NTORS). Crim. Behav. Ment. Health 2000, 10:10-20.
39. Strathdee S.A., Patrick D.M., Currie S.L., Cornelisse P.G., Rekart M.L., Montaner J.S., Schechter M.T., O'Shaughnessy M.V. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997, 11:F59-F65.
40. Substance Abuse and Mental Health Services Administration Treatment Episode Data Set (TEDS): 2001-2011 2013, Center for Behavioral Health Statistics and Quality, (Publication no. (SMA) 13-4772, accessed on 17 December 2013).
41. Termorshuizen F., Krol A., Prins M., Geskus R., van den Brink W., van Ameijden E.J. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend. 2005, 79:231-240.
42. Tyndall M.W., Currie S., Spittal P., Li K., Wood E., O'Shaughnessy M.V., Schechter M.T. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003, 17:887-893.
43. Wall R., Rehm J., Fischer B., Brands B., Gliksman L., Stewart J., Medved W., Blake J. Social costs of untreated opioid dependence. J. Urban Health 2000, 77:688-722.
44. Wood E., Stoltz J.A., Li K., Montaner J.S., Kerr T. Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction 2006, 101:689-695.
45. Wood E., Stoltz J.A., Montaner J.S., Kerr T. Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct. J. 2006, 3:18.
46. Wood E., Kerr T., Marshall B.D.L., Li K., Zhang R., Hogg R.S., Harrigan P.R., Montaner J.S.G. Longitudinal community plasma HIV-1-RNA concentrations and incidence of HIV-1 among injecting drug users: a prospective cohort study. BMJ 2009, 338:1191-1194.
47. Zarkin G.A., Dunlap L.J., Hicks K.A., Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005, 14:1133-1150.
48. Zarkin G.A., Cowell A.J., Hicks K.A., Mills M.J., Belenko S., Dunlap L.J., Houser K.A., Keyes V. Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model. Health Econ. 2012, 21:633-652.